ANALYSIS OF COST AND EFFECTIVENESS OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION AMONG PATIENTS WITH AGGRESSIVE MULTIPLE SCLEROSIS IN POLAND
Author(s)
Orlewska K1, Sliwczynski A2, Snarski E1
1Medical University of Warsaw, Warsaw, Poland, 2National Health Fund, Warsaw, Poland
OBJECTIVES: Autologous hematopoietic stem cell transplantation (AHSCT) has been recently proposed as treatment option for patients with aggressive multiple sclerosis (MS). The study aimed to assess the clinical and economic benefits of AHSCT among aggressive MS patients in Poland. METHODS: This is a retrospective database analysis with pre and post study design. 89 patients (78 with relapsing-remitting MS, 11 with secondary progressive MS, median age 38, 55% women) with aggressive MS who underwent AHSCT in 2011-2016 were identified from the National Health Fund (NHF) database. Direct medical costs were calculated from public payer’s perspective and expressed in PLN (1 PLN=0.23 € (2018)) per patient/year for the total period before and after AHSCT covered in the database (402 patient-years) and 12 months before and after the procedure. Clinical data was derived from published clinical report. The effectiveness was measured as median Expanded Disability Status Scale (EDSS) before and after AHSCT and as % of patients with NEDA (defined as absence of relapses, no disability progression nor radiological activity detected by magnetic resonance). RESULTS: Median EDSS decreased from 5.0 to 4.25 after AHSCT. 3-year NEDA was observed among 74% of patients. No mortality and long-term side effects were recorded. Mean cost per patient/year before and after the transplantation was 17,079 PLN and 4,494 PLN, respectively. For the 12-months period before and after AHSCT mean cost per patient amounted to 23,032 PLN vs 4,438 PLN. Given that AHSCT is a onetime cost of 52,000 PLN, the payback period is 4 years (2.8 years if considering 12-month period costs only). The cost of disease modifying drug administration reduced from 4,680 PLN before to 265 PLN after AHSCT. CONCLUSIONS: AHSCT not only proved to supress the disease activity, but also lower its economic burden. Our results support AHSCT as effective treatment option of aggressive MS.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PND52
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders